WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 9 fonti

Samsung Biologics expands into peptides with $1.8b PolyPeptide deal

Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its mult

Raccontata daswissinfo.chcnbc.comkoreatimes.co.krkoreaherald.commilanofinanza.itrsi.chforbes.itfiercepharma.comendpoints.news

Confronto fonti

6 prospettive sulla stessa storia
AI · summaries
koreaherald.comStai leggendo2 g fa

Samsung Biologics expands into peptides with $1.8b PolyPeptide deal

Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its mult

originale

Timeline cronologica

  1. lunedì 20 luglio 2026·swissinfo.ch

    Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal

    (Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…

  2. lunedì 20 luglio 2026·cnbc.com

    Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal

    South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.

koreatimes.co.kr
2 g fa

Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times

Samsung Biologics said Monday it will acquire Swiss peptide drug manufacturer PolyPeptide Group through an all-cash public tender offer valued at a...

Leggi questa versione → originale
swissinfo.ch2 g fa

Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal

(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion Swiss francs ($1.8 billion), expanding its…

Leggi questa versione → originale
fiercepharma.com2 g fa

Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide

South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO PolyPeptide for 1.46 billio | South Korean…

Leggi questa versione → originale
cnbc.com2 g fa

Samsung Biologics to acquire Switzerland's PolyPeptide Group in $1.8 billion all-cash deal

South Korea's Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group.

Leggi questa versione → originale
endpoints.news2 g fa

Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker

Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1 manufacturing market.

Leggi questa versione → originale
  • lunedì 20 luglio 2026·koreatimes.co.kr

    Samsung Biologics to acquire PolyPeptide for $1.8 bil. - The Korea Times

    Samsung Biologics said Monday it will acquire Swiss peptide drug manufacturer PolyPeptide Group through an all-cash public tender offer valued at a...

  • lunedì 20 luglio 2026·koreaherald.com

    Samsung Biologics expands into peptides with $1.8b PolyPeptide deal

    Samsung Biologics said Monday it has launched a $1.8 billion all-cash bid to acquire 100 percent of PolyPeptide, entering the peptide sector to bolster its mult

  • lunedì 20 luglio 2026·milanofinanza.it

    Samsung Biologics, opa da 1,8 miliardi sulla svizzera PolyPeptide: focus sui farmaci dimagranti | MilanoFinanza News

    La controllata del gruppo Samsung lancia un'opa da 1,46 miliardi di franchi svizzeri (1,8 miliardi di dollari) su PolyPeptide per rafforzarsi nei farmaci peptidici, trainati dalla…

  • lunedì 20 luglio 2026·rsi.ch

    Offerta miliardaria per l’elvetica PolyPeptide - RSI

    Samsung Biologics offre 1,5 miliardi di franchi per acquisire PolyPeptide, produttore svizzero di peptidi. Il CdA elvetico sostiene l'offerta.

  • lunedì 20 luglio 2026·swissinfo.ch

    Korean firm bids CHF1.5bn for Swiss pharma supplier Polypeptide

    South Korean biopharmaceutical Samsung Biologics bids for Swiss pharma ingredient firm Polypeptide.

  • lunedì 20 luglio 2026·forbes.it

    Samsung Biologics punta al mercato dei farmaci anti-obesità: opa da 1,8 miliardi sulla svizzera PolyPeptide

    Samsung Biologics lancia un'opa da 1,8 miliardi di dollari su PolyPeptide. Il colosso sudcoreano punta sulle terapie peptidiche

  • lunedì 20 luglio 2026·fiercepharma.com

    Samsung Biologics spreads wings with proposed $1.8B acquisition of Swiss CDMO PolyPeptide

    South Korean contract manufacturer Samsung Biologics hopes to tap into the booming peptide production and weight loss market with plans to buy out Switzerland-based CDMO…

  • lunedì 20 luglio 2026·endpoints.news

    Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker

    Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1 manufacturing market.